Crossmark

Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer

Crossref DOI link: https://doi.org/10.1186/s13048-019-0506-4

Published Online: 2019-04-25

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cohen, Samantha

Schwartz, Melissa http://orcid.org/0000-0003-2968-6459
Dottino, Peter

Beddoe, Ann Marie
License Information

Text and Data Mining valid from 2019-04-25
More Information

Article History

Received: 31 July 2018

Accepted: 29 March 2019

First Online: 25 April 2019

Ethics approval and consent to participate

: Ethics approval was obtained for this retrospective study via the Icahn School of Medicine Institutional Review Board (IRB-16-00857).

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below